Lewy body disease (LBD) is the second most common degenerative brain disorder after Alzheimer’s disease, yet it remains under-recognized. Affecting more than 1.3 million Americans, LBD is frequently misdiagnosed and diagnosis is often delayed. Patients experience a complex mix of cognitive decline, motor impairment, and behavioral changes. High-profile cases, such as the late actor Robin Williams and NHL coach Alger Joseph “Radar” Arbour, have raised awareness because LBD can cause vivid visual hallucinations and worsen mood disorders like depression. Until recently, clinicians lacked a brief, practical method to capture many of the cognitive and behavioral features that point to LBD in everyday practice.
To address this gap, a leading neuroscientist at Florida Atlantic University developed the Lewy Body Composite Risk Score (LBCRS), a simple clinician-administered screening tool that can help detect LBD and Parkinson’s disease dementia (PDD) in about three minutes. The LBCRS is a concise, one-page survey consisting of structured yes/no items that document clinical signs and non-motor symptoms strongly associated with Lewy body pathology but less common in other dementias. It allows clinicians to note bradykinesia, rigidity, postural instability, or resting tremor without detailed limb-by-limb grading, and to record non-motor features that frequently accompany LBD.
The LBCRS was evaluated in a study titled “Improving the Clinical Detection of Lewy Body Dementia with the Lewy Body Composite Risk Score,” published in the journal Alzheimer’s & Dementia. The study enrolled 256 consecutive clinic patients and compared LBCRS results with clinical dementia ratings and established measures of cognition, motor function, daily functioning, and behavior. Importantly, the research took place in a real-world clinical setting with community-referred patients, representing a diverse mix of genders, educational backgrounds, medical comorbidities, behavioral and affective symptoms, motor signs, and diagnostic categories. In this heterogeneous clinical sample, the LBCRS distinguished Alzheimer’s disease from LBD with 96.8 percent overall accuracy, demonstrating 90 percent sensitivity and 87 percent specificity.
Caregivers completed structured evaluations that documented the presence and severity of non-cognitive symptoms and their impact on the caregiver. Each patient received a 30-minute cognitive testing battery during the clinic visit, and the LBCRS was completed after other rating scales had been scored and diagnostic impressions were formed and discussed with the patient and family.
“Most patients never receive an evaluation by a neurologist specialized in Lewy body dementia, and many experience long diagnostic delays or incorrect diagnoses,” said James E. Galvin, M.D., M.P.H., the developer of the LBCRS and a professor at Florida Atlantic University’s Charles E. Schmidt College of Medicine and Christine E. Lynn College of Nursing. “This brief tool can help non-specialist clinicians recognize the clinical signs that suggest Lewy body pathology, speeding correct diagnosis and reducing the emotional and practical burden on patients and caregivers.”
Beyond improving diagnostic recognition, the LBCRS can reduce exposure of patients with LBD to medications that carry severe risks for this population, and it can increase timely access to appropriate symptomatic treatments. Better screening also helps ensure more accurate inclusion and exclusion in clinical trials and research studies, avoiding the misclassification that can confound trial results.
Early and accurate identification of Lewy body dementias is crucial for future therapies that will likely work best when started at the earliest stages of disease. According to Galvin, the LBCRS provides an evidence-based method that can be used in clinical practice, clinical trials, community surveys, prevention research, and biomarker studies.
Galvin is an international expert on LBD who has worked to refine clinical detection through multimodal biomarker approaches, including high-density EEG, functional and structural MRI, PET imaging, and cerebrospinal fluid assays, to better separate LBD from healthy aging and other neurodegenerative disorders. He has also led the development and validation of several dementia screening instruments designed for rapid use in clinic and community settings, such as the Quick Dementia Rating System (QDRS) and the AD8 informant interview.
His research team has validated screening tools against gold-standard clinical evaluations and biomarker measures, performed cross-cultural validation studies, and developed statistical models to explore transitions across clinical, cognitive, functional, behavioral, and biological markers in healthy aging, mild cognitive impairment, Alzheimer’s disease, and Parkinson’s disease.
Source: Gisele Galoustian, Florida Atlantic University
Image credit: Dr. Andreas Becker (image used for illustrative purposes)
Original research: James E. Galvin, “Improving the Clinical Detection of Lewy Body Dementia with the Lewy Body Composite Risk Score,” published in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. Published online July 2, 2015. DOI: 10.1016/j.dadm.2015.05.004
Abstract
Improving the clinical detection of Lewy body dementia with the Lewy Body Composite Risk Score
Introduction
Dementia with Lewy bodies (DLB) is difficult to diagnose, particularly outside specialized centers, and long diagnostic delays increase the burden on patients and caregivers. Although existing consensus criteria are highly specific, standardized methods to assess the characteristic symptoms are lacking, which reduces sensitivity. The Lewy Body Composite Risk Score (LBCRS) was developed using autopsy-verified cases to improve detection of DLB in both clinical and research populations.
Methods
The LBCRS was evaluated in a consecutive series of 256 patients and compared with clinical dementia ratings and established measures of cognition, motor function, everyday function, and behavior. Psychometric properties were assessed, including floor and ceiling effects, concurrent and construct validity, known-groups validity, and internal consistency. Receiver operating characteristic (ROC) analyses measured the LBCRS’s ability to differentiate (1) DLB from Alzheimer’s disease (AD), (2) DLB from all causes of dementia, and (3) mild cognitive impairment due to DLB from MCI due to AD. The LBCRS was completed independently of the clinical evaluation.
Results
Mean LBCRS scores differed significantly between DLB and AD (6.1 ± 2.0 vs. 2.4 ± 1.3, P < .001) and between MCI-DLB and MCI-AD (3.2 ± 0.9 vs. 1.0 ± 0.8, P < .001). Using a cutoff score of 3, area under the ROC curve for DLB versus AD was 0.93 (0.89–0.98), and for MCI-DLB versus MCI-AD was 0.96 (0.91–1.0), indicating strong discriminative ability.
Discussion
The LBCRS raises the probability that Lewy body pathology contributes to a patient’s dementia syndrome and should improve clinical detection and enrollment for clinical trials. As a rapid, practical screening instrument, it supports earlier recognition, safer medication choices, and better-targeted therapeutic and research interventions for Lewy body dementias.